SCHEMBL31227299

SCHEMBL31227299

O=C(Cl)c1ccc(Br)nc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NAPRT Q6XQN6 1/20 0.45
▸ P4HA1 P13674 2/20 0.39
▸ P4HTM Q9NXG6 2/20 0.39
▸ MIF P14174 1/20 0.38
▸ GRM4 Q14833 2/20 0.37
▸ EGFR P00533 1/20 0.37
▸ HDAC1 Q13547 2/20 0.37
▸ HDAC6 Q9UBN7 2/20 0.37
▸ FDFT1 P37268 1/20 0.37
▸ NNMT P40261 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ GABRP O00591 1/20 0.36
▸ GABRD O14764 1/20 0.36
▸ GABRA1 P14867 1/20 0.36
▸ GABRB1 P18505 1/20 0.36
▸ GABRG2 P18507 1/20 0.36
▸ GABRB3 P28472 1/20 0.36
▸ GABRA5 P31644 1/20 0.36
▸ GABRA3 P34903 1/20 0.36
▸ GABRA2 P47869 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL960056 1.00 NAPRT (0.45) NAPRTP4HA1P4HTMMIFGRM4
SCHEMBL5973043 0.82 RXFP1 (0.44) NAPRTP4HA1P4HTMMIFHDAC1
SCHEMBL29751460 0.80 P4HA1 (0.61) NAPRTP4HA1P4HTMMIFALDH1A1
SCHEMBL7312742 0.80 P4HA1 (0.40) NAPRTP4HA1P4HTMMIFHDAC1
SCHEMBL38414 0.80 P4HA1 (0.61) NAPRTP4HA1P4HTMMIFALDH1A1
SCHEMBL15773930 0.78 NAPRT (0.41) NAPRTP4HA1P4HTMMIFGRM4
SCHEMBL22229965 0.78 NNMT (0.61) NNMTL3MBTL1SMN1; SMN2
Hydrochloric Acid SCHEMBL1871783 0.78 P4HA1 (0.59) NAPRTP4HA1P4HTMMIFALDH1A1
SCHEMBL690853 0.78 KCNJ1 (0.46) P4HA1P4HTMMIFHDAC1HDAC6
SCHEMBL29480657 0.78 KCNJ1 (0.46) P4HA1P4HTMMIFHDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors INITIAL THERAPEUTICS, INC. (US) 2024-12-05 — — US disclosed
WO-2024226875-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS INITIAL THERAPEUTICS, INC. (US) 2024-10-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors MYCBP, MYC, MYCBP2 NAPRT 1588/4885P4HA1 1170/4885P4HTM 1931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback